V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20104797 | 20134005 | 1.82 | 67.4 | null | 2016-12-20 | 2016-12-27 | CYTARABINE + DAUNORUBICIN + Gemtuzumab Ozogamicin | 02 | null | INTERAACT TRIAL | 100114065 |
| 20104849 | 20134006 | 1.82 | 10.8 | null | 2019-05-05 | 2019-05-05 | MITOMYCIN | 02 | N | CARBOPLATIN + VINORELBINE | 101653900 |
| 20104903 | 20134007 | 1.82 | 0 | null | 2012-01-02 | 2017-08-11 | Gemcitabine + RT pancreas | 02 | null | AFATINIB | 101304581 |
| 20105104 | 20134008 | 1.82 | 63.7 | Palliative (P) | null | 2020-10-27 | CAPECITABINE + IRINOTECAN + Panitumumab | null | N | CARBOPLATIN + EPIRUBICIN + FLUOROURACIL | 101156254 |
| 20105167 | 20134009 | 1.57 | null | null | 2018-06-15 | 2018-06-16 | FCiSt | 02 | null | BENDAMUSTINE + RITUXIMAB | 101586936 |
| 20105531 | 20134011 | 1.85 | null | Neo-adjuvant (N) | 2020-12-06 | 2020-12-06 | RUXOLITINIB | N | N | FOXTROT TRIAL | 100928880 |
| 20105807 | 20134013 | 1.8 | 62.5 | Adjuvant (A) | 2019-09-30 | 2019-12-02 | IBRUTINIB | 01 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100908438 |
| 20105865 | 20134014 | null | null | null | 2018-02-03 | 2018-02-03 | BCG Intravesical | 02 | null | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 100094039 |
| 20106119 | 20134015 | 1.71 | 74 | Palliative (P) | 2016-08-19 | 2016-08-20 | Carboplatin + Cetux + FU (Cycle 1) | 02 | N | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 101121579 |
| 20106237 | 20134017 | 1.53 | 60.6 | Palliative (P) | 2017-05-26 | 2017-05-26 | MITOMYCIN | 02 | N | CAPECITABINE + STREPTOZOCIN | 100563912 |
| 20106347 | 20134018 | 1.65 | 15.5 | Curative (C) | 2016-09-16 | 2016-09-23 | Carboplatin + Cetux + FU (Cycle 1) | 1 | null | ETOPOSIDE | 101267204 |
| 20106380 | 20134019 | 1.47 | 79.2 | null | 2018-09-07 | 2018-10-02 | IPILIMUMAB + NIVOLUMAB | null | null | CISPLATIN + CYTARABINE + ETOPOSIDE + RITUXIMAB | 101262797 |
| 20106400 | 20134020 | 1.54 | 44.9 | Palliative (P) | 2018-07-25 | 2018-07-25 | HEP HR Hepatoblastoma gde carbo dox | 02 | null | BORTEZOMIB + DARATUMUMAB | 100735055 |
| 20106458 | 20134021 | 1.67 | 73 | Palliative (P) | 2019-09-21 | 2019-10-09 | AFLIBERCEPT + FLUOROURACIL + IRINOTECAN | 02 | N | NINTEDANIB | 101531659 |
| 20106829 | 20134022 | 1.77 | 76 | Curative (C) | 2018-02-26 | 2018-03-27 | IPILIMUMAB + NIVOLUMAB | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100609154 |
| 20106930 | 20134023 | 1.63 | 57 | null | 2020-11-22 | 2020-12-10 | IBRUTINIB | 02 | null | OSIMERTINIB | 101426233 |
| 20107420 | 20134024 | 1.56 | 53.2 | Curative (C) | null | 2019-10-03 | CISPLATIN + TEYSUNO | 2 | N | PERTUZUMAB | 100403861 |
| 20107491 | 20134025 | 1.65 | 108.1 | Palliative (P) | 2019-06-23 | 2019-06-29 | null | 02 | N | DOXORUBICIN | 101526053 |
| 20107700 | 20134026 | 1.52 | 61.8 | Palliative (P) | 2018-06-13 | 2018-08-17 | BORTEZOMIB + DARATUMUMAB + THALIDOMIDE | 02 | N | DARATUMUMAB | 101566200 |
| 20108059 | 20134028 | 1.8 | 88.8 | null | 2017-04-22 | 2017-05-07 | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 02 | null | LIPOSOMAL DAUNORUBICIN + LIPOSOMAL CYTARABINE (VYXEOS) | 101609991 |
| 20108076 | 20134029 | null | 70.2 | Neo-adjuvant (N) | 2017-07-31 | 2017-08-06 | PACLITAXEL + TRASTUZUMAB | 02 | N | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 100182478 |
| 20108324 | 20134030 | 1.52 | 61.8 | Adjuvant (A) | 2016-05-13 | 2016-10-16 | Alectinib | 02 | N | TRABECTEDIN | 100691809 |
| 20108362 | 20134031 | 1.84 | 17.9 | Palliative (P) | 2019-11-21 | 2019-11-22 | IBRUTINIB | 02 | N | CAV | 101013967 |
| 20108402 | 20134032 | 1.84 | 55.05 | null | 2019-11-18 | 2019-12-10 | IBRUTINIB | 02 | null | LIPOSOMAL DAUNORUBICIN + LIPOSOMAL CYTARABINE (VYXEOS) | 101769870 |
| 20108736 | 20134033 | 1.58 | 93.4 | Curative (C) | 2017-09-25 | 2017-09-29 | Gemcitabine + RT pancreas | N | N | ARISTOTLE TRIAL | 100468534 |
| 20108821 | 20134034 | 1.71 | 63.7 | Palliative (P) | 2017-11-13 | 2017-12-12 | CAM-PLEX Trial | 02 | N | CAPECITABINE + LOMUSTINE | 101861857 |
| 20108902 | 20134035 | 1.56 | 88 | Palliative (P) | 2019-01-09 | 2019-01-17 | Temozolomide 200mg/m2 | 02 | N | FOXTROT TRIAL | 100854301 |
| 20109556 | 20134036 | 0.7 | 80 | null | 2021-11-16 | 2021-11-23 | Rituximab | 02 | N | IBRUTINIB | 101711471 |
| 20109923 | 20134037 | 1.81 | 102.1 | null | 2016-08-05 | 2016-08-13 | VDC | 02 | N | IBRUTINIB | 101417972 |
| 20110305 | 20134038 | 1.57 | 71.2 | Curative (C) | 2018-12-04 | 2018-12-04 | Bevacizumab + FLUOROURACIL + IRINOTECAN | 02 | null | DARATUMUMAB | 101653892 |
| 20110317 | 20134039 | 1.7 | 65 | Palliative (P) | 2019-06-29 | 2019-07-12 | Cisplatin + Fluorouracil + RT 5day | 02 | N | BORTEZOMIB + DARATUMUMAB | 101063964 |
| 20110391 | 20134040 | null | 46 | Palliative (P) | 2015-11-12 | 2015-11-28 | CHOP R - 21 days | 02 | N | HEPATOBLASTOMA SR CISPLATIN | 100047149 |
| 20110422 | 20134041 | 1.86 | 63 | Palliative (P) | 2019-04-26 | 2019-05-12 | Cisplatin + Fluorouracil + RT 5day | 02 | N | FOCUS4 TRIAL | 101057072 |
| 20111083 | 20134044 | 1.87 | 46.2 | Palliative (P) | 2017-09-09 | 2017-09-12 | CISPLATIN + FLUOROURACIL + RT | 02 | N | DERAZANTINIB | 101287389 |
| 20111191 | 20134046 | null | null | Palliative (P) | 2020-01-01 | 2020-03-25 | ECF | 02 | N | GEMCITABINE + PACLITAXEL | 100997276 |
| 20111387 | 20134047 | 1.57 | 82.5 | Curative (C) | 2016-10-15 | 2018-10-16 | Hydroxycarbamide | 02 | N | GEMCITABINE + OXALIPLATIN | 101824299 |
| 20112076 | 20134049 | 1.84 | 73.8 | null | 2019-04-27 | 2019-05-18 | Capecitabine + Streptozocin | 02 | null | CARBOPLATIN + PEMETREXED | 101860498 |
| 20112199 | 20134050 | null | 56.1 | null | 2019-07-30 | 2019-08-01 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | CAP + RT | 101722338 |
| 20112298 | 20134052 | 1.58 | 80.05 | Palliative (P) | 2016-06-05 | 2016-06-05 | Atezolizumab | 02 | Y | RITUXIMAB | 101600163 |
| 20112310 | 20134053 | 1.69 | 108 | Palliative (P) | 2020-03-29 | 2021-01-07 | GEFITINIB | N | N | FLUOROURACIL + OXALIPLATIN + PEMBROLIZUMAB | 100275376 |
| 20112329 | 20134054 | 1.75 | 88 | Curative (C) | null | 2018-07-25 | ECF | N | N | ETOPOSIDE | 101540728 |
| 20112410 | 20134055 | 1.74 | 76 | 03 | 2021-03-21 | 2021-08-10 | EOF | 99 | null | CISPLATIN + FLUOROURACIL + STREPTOZOCIN | 101365980 |
| 20112682 | 20134057 | 1.85 | 66.7 | null | 2020-04-26 | 2020-04-26 | Pertuzumab + Trastuzumab IV | N | null | DOXORUBICIN | 100909926 |
| 20112751 | 20134058 | 1.65 | 47.2 | Disease modification (D) | 2018-04-24 | 2018-05-01 | TCH (21 day Trastuzumab) Loading | 02 | N | IFOSFAMIDE | 101260811 |
| 20112881 | 20134059 | 1.53 | 8.9 | Curative (C) | 2018-06-11 | 2018-06-14 | Atezolizumab | N | N | CYCLOPHOSPHAMIDE HIGH DOSE | 101400442 |
| 20112947 | 20134060 | 1.58 | 70 | null | 2019-09-10 | 2019-11-06 | Etoposide oral | 02 | N | CARBOPLATIN + RT | 101334648 |
| 20113008 | 20134061 | 1.8 | 24.4 | Adjuvant (A) | null | 2018-08-30 | CHOP R - 21 days | null | N | BORTEZOMIB + THALIDOMIDE | 100159269 |
| 20113049 | 20134062 | 1 | 62.8 | Palliative (P) | 2020-10-15 | 2020-10-15 | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 02 | N | CARBOPLATIN + TEYSUNO | 101853600 |
| 20113162 | 20134063 | 1.81 | 66.5 | Palliative (P) | 2020-02-11 | 2020-02-18 | PEG INTERFERON | N | null | RITUXIMAB | 100061610 |
| 20113281 | 20134065 | 1.85 | 94.2 | Adjuvant (A) | 2020-02-11 | 2020-03-21 | CAV | null | N | CARBOPLATIN + FLUOROURACIL + STREPTOZOCIN | 101332264 |